Tevogen Inc.
No SEC Form 4 filings for $TVGN in the last 30 days.
See all $TVGN insider activity →Tevogen Inc. (TVGN) signed a non-binding LOI to evaluate acquiring HRK Healthcare LLC, potentially expanding its healthcare services and targeting $100M in combined annual revenue if completed. The deal is in early stages, with no definitive agreement or terms disclosed yet, according to the company.
Tevogen Bio Holdings has regained compliance with Nasdaq's minimum market value requirement. The company's stock has seen a 5-day change of 6.620 USD, a 1st Jan change of -1.93%, and a year-to-date change of -60.01%.
Tevogen Inc. (TVGN) announced it has regained compliance with Nasdaq's $50 million minimum market value requirement for listed securities, closing related compliance matters. The company previously met another compliance requirement on September 9, 2026.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TVGN (Tevogen Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent TVGN coverage spans corporate actions, financial news and market movers.
The LOI could expand Tevogen's healthcare services and add significant revenue if completed.
Regaining Nasdaq compliance removes a delisting risk, likely supporting the stock.
Regaining compliance removes delisting risk and may support the stock price.
Regaining Nasdaq compliance removes delisting risk and may support a modest price bounce.
The large performance‑based grant aligns insider incentives with future revenue growth, potentially supporting upside if the target is met.
AlphAI scores every news story that mentions TVGN with an AI model for sentiment and relevance, and aggregates insider trades from Tevogen Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tevogen Inc. (TVGN) signed a non-binding LOI to evaluate acquiring HRK Healthcare LLC, potentially expanding its healthcare services and targeting $100M in combined annual revenue if completed. The deal is in early stages, with no definitive agreement or terms disclosed yet, according to the company.
2 min readTevogen Bio Holdings has regained compliance with Nasdaq's minimum market value requirement. The company's stock has seen a 5-day change of 6.620 USD, a 1st Jan change of -1.93%, and a year-to-date change of -60.01%.
1 min readTevogen Inc. (TVGN) announced it has regained compliance with Nasdaq's $50 million minimum market value requirement for listed securities, closing related compliance matters. The company previously met another compliance requirement on September 9, 2026.
1 min readTevogen Inc. (TVGN) announced it has regained compliance with Nasdaq's $50M minimum market value requirement. The company previously met the minimum public float rule, closing related compliance matters. Tevogen focuses on healthcare, biotech, AI, and services to improve medicine affordability and access.
1 min readTevogen Inc. (TVGN) reports Ryan H. Saadi now owns 74.4% of its shares, including 9.77M restricted shares. The company granted Saadi 8M additional restricted shares, vesting only if TVGN achieves $1B in revenue by 2031.
1 min readTevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Restricted Stock Awards On September 14, 2026 (the “Grant Date”), Tevogen Inc. (the “Company”) granted the Company’s execut
1 min readTevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 24, 2026, Tevogen Inc. (the “Company”) held an annual meeting of its stockholders (the “Annual Meeting”). As note
1 min readBiotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
6 min readTevogen Bio Holdings (Nasdaq: TVGN) said it formed a healthcare services initiative to broaden its revenue-generating business. William Keane, VP Strategic Initiatives, will lead it interim while the company evaluates acquiring an MSO and CRO. Tevogen estimates the potential combined annual revenue at about $100 million, subject to deal completion.
3 min readSciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.
6 min read
